A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression
Triple-negative breast cancer (TNBC) is the most malignant type of breast cancer and lacks effective targeted therapeutic drugs, resulting in a high recurrence rate and worse outcome. In this study, bioinformatic analysis and a series of experiments demonstrated that MOCR2 was highly expressed in TN...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006425000559 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590860358778880 |
|---|---|
| author | Xiaohan Su Yunbo Luo Yali Wang Peng Qu Jun Liu Shiqi Han Cui Ma Shishan Deng Qi Liang Xiaowei Qi Panke Cheng Lingmi Hou |
| author_facet | Xiaohan Su Yunbo Luo Yali Wang Peng Qu Jun Liu Shiqi Han Cui Ma Shishan Deng Qi Liang Xiaowei Qi Panke Cheng Lingmi Hou |
| author_sort | Xiaohan Su |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is the most malignant type of breast cancer and lacks effective targeted therapeutic drugs, resulting in a high recurrence rate and worse outcome. In this study, bioinformatic analysis and a series of experiments demonstrated that MOCR2 was highly expressed in TNBC and closely associated with poor prognosis, indicating that MOCR2 may be a potential therapeutic target for TNBC. Subsequently, Angoline was identified as an inhibitor of MORC2 protein by high-throughput screening and can significantly kill the TNBC cells by blocking cell cycle and inducing apoptosis. Furthermore, the biomimetic nanodrug delivery system (PMD) was designed by encapsulating tetrahedral DNA nanostructures with biomimetic cell membrane, and it can efficiently evade the phagocytosis of immune system and target TNBC tissue. Additionally, PMD can markedly enhance the killing effect of Angoline on TNBC tumors. Therefore, PMD-enveloped Angoline provide a highly effective targeted therapeutic regimen for TNBC and may improve the outcome for patients with TNBC. |
| format | Article |
| id | doaj-art-080383faf13c4b7c9eb75830deab488e |
| institution | Kabale University |
| issn | 2590-0064 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj-art-080383faf13c4b7c9eb75830deab488e2025-01-23T05:27:38ZengElsevierMaterials Today Bio2590-00642025-04-0131101497A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progressionXiaohan Su0Yunbo Luo1Yali Wang2Peng Qu3Jun Liu4Shiqi Han5Cui Ma6Shishan Deng7Qi Liang8Xiaowei Qi9Panke Cheng10Lingmi Hou11Breast Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; Department of Breast Surgery, Mianyang 404 hospital, Mianyang, ChinaBreast Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; Department of Breast and Thyroid Surgery, Biological Targeting Laboratory of Breast Cancer, Academician (expert) Workstation, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Breast and Thyroid Surgery, Biological Targeting Laboratory of Breast Cancer, Academician (expert) Workstation, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Laboratory Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaInstitute of Cardiovascular Diseases & Department of Cardiology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaDepartment of Breast and Thyroid Surgery, Biological Targeting Laboratory of Breast Cancer, Academician (expert) Workstation, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Mathematics, Army Medical University, Chongqing, ChinaDepartment of Breast and Thyroid Surgery, Biological Targeting Laboratory of Breast Cancer, Academician (expert) Workstation, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Laboratory Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, ChinaDepartment of Breast Surgery, Southwest Hospital, Army Medical University, Chongqing, China; Corresponding author.Institute of Cardiovascular Diseases & Department of Cardiology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; Ultrasound in Cardiac Electrophysiology and Biomechanics Key Laboratory of Sichuan Province, Chengdu, China; Corresponding author. Institute of Cardiovascular Diseases & Department of Cardiology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.chengpk1002@163.comBreast Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; Corresponding author.Triple-negative breast cancer (TNBC) is the most malignant type of breast cancer and lacks effective targeted therapeutic drugs, resulting in a high recurrence rate and worse outcome. In this study, bioinformatic analysis and a series of experiments demonstrated that MOCR2 was highly expressed in TNBC and closely associated with poor prognosis, indicating that MOCR2 may be a potential therapeutic target for TNBC. Subsequently, Angoline was identified as an inhibitor of MORC2 protein by high-throughput screening and can significantly kill the TNBC cells by blocking cell cycle and inducing apoptosis. Furthermore, the biomimetic nanodrug delivery system (PMD) was designed by encapsulating tetrahedral DNA nanostructures with biomimetic cell membrane, and it can efficiently evade the phagocytosis of immune system and target TNBC tissue. Additionally, PMD can markedly enhance the killing effect of Angoline on TNBC tumors. Therefore, PMD-enveloped Angoline provide a highly effective targeted therapeutic regimen for TNBC and may improve the outcome for patients with TNBC.http://www.sciencedirect.com/science/article/pii/S2590006425000559MORC2AngolineBiomimetic nanodrug delivery systemTriple-negative breast cancer |
| spellingShingle | Xiaohan Su Yunbo Luo Yali Wang Peng Qu Jun Liu Shiqi Han Cui Ma Shishan Deng Qi Liang Xiaowei Qi Panke Cheng Lingmi Hou A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression Materials Today Bio MORC2 Angoline Biomimetic nanodrug delivery system Triple-negative breast cancer |
| title | A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression |
| title_full | A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression |
| title_fullStr | A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression |
| title_full_unstemmed | A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression |
| title_short | A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression |
| title_sort | select inhibitor of morc2 encapsulated by chimeric membranecoated dna nanocage target alleviation tnbc progression |
| topic | MORC2 Angoline Biomimetic nanodrug delivery system Triple-negative breast cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2590006425000559 |
| work_keys_str_mv | AT xiaohansu aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT yunboluo aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT yaliwang aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT pengqu aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT junliu aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT shiqihan aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT cuima aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT shishandeng aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT qiliang aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT xiaoweiqi aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT pankecheng aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT lingmihou aselectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT xiaohansu selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT yunboluo selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT yaliwang selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT pengqu selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT junliu selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT shiqihan selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT cuima selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT shishandeng selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT qiliang selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT xiaoweiqi selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT pankecheng selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression AT lingmihou selectinhibitorofmorc2encapsulatedbychimericmembranecoateddnananocagetargetalleviationtnbcprogression |